Skip to main content
Premium Trial:

Request an Annual Quote

Intercardia Offers $15 Million to Acquire Transcell Technologies

Premium

RESEARCH TRIANGLE PARK, NC--Drug development company Intercardia here is aggressively expanding, with the company's most recent move being to sign a letter of intent to acquire combinatorial chemistry company Transcell Technologies, Monmouth Junction, NJ. Signed in November, the deal calls for Intercardia to pay approximately $15 million in stock for Transcell, which has a $48 million deal with Merck to discover and evaluate two antibacterial compounds.

The agreement specifies that Transcell shareholders will receive three installments of Intercardia stock worth a total of approximately $4 million. In addition, Inter cardia will issue stock options worth $3 million-$4 million to Transcell employees and issue $4 million of its stock to parent company Interneuron for other Transcell technology. Earlier last year, Intercardia acquired an 80 percent ownership of Renaissance Cell Technologies, which is focused on harnessing the growth potential of stem cells.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.